CALAN® SR Principal Display Panel (verapamil sustained release oral caplets)

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PRINCIPAL DISPLAY PANEL - 120 mg Tablet Bottle Label

NDC 0025-2712-31
Pfizer

Calan® SR
(verapamil hydrochloride)
extended-release tablets

120 mg*

100 Tablets
Rx only

PRINCIPAL DISPLAY PANEL - 180 mg Tablet Bottle Label

NDC 0025-2818-31
Pfizer

Calan® SR
(verapamil hydrochloride)
extended-release tablets

180 mg*

100 Tablets
Rx only

PRINCIPAL DISPLAY PANEL - 240 mg Tablet Bottle Label

NDC 0025-2924-31
Pfizer

Calan® SR
(verapamil hydrochloride)
extended-release tablets

240 mg*

100 Tablets
Rx only

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

CALAN® SR Quick Finder

Report an adverse event or concern about the quality of a Pfizer product

To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly by visiting www.fda.gov/medwatch or by calling (800)-332-1088.
Assistance programs (for eligible patients)

Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. Patients and physicians can contact RxPathways at (866) 706-2400 or visit the website for more information on these programs www.pfizerrxpathways.com.
Resources

Show All Hide All

INDICATIONS AND USAGE

CALAN SR is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial...